Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482625 · ClinicalTrials.gov registry record · Phase 2
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00482625: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00482625 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00482625, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. This phase II trial is studying how well erlotinib hydrochloride works in treating patients with pancreatic cancer that can be removed by surgery
Interventions
- GENETIC protein expression analysis
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- PROCEDURE conventional surgery
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00482625
The ClinicalTrials.gov registry entry for NCT00482625 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00482625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00482625 about?
NCT00482625 is a clinical study titled "Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery". Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. This phase II trial is studying how well erloti...
What is the current status of trial NCT00482625?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2007-06. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00482625?
The interventions under investigation include: protein expression analysis (GENETIC), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), conventional surgery (PROCEDURE), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00482625?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.